Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JCOG1205/1206 adjuvant cisplatin-based chemotherapy trial in resected pulmonary high-grade neuroendocrine carcinoma
jRCTs031180216Phase 3Completed
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Lung neuroendocrine carcinoma (LNEC) comparing Etoposide + Cisplatin with Irinotecan + Cisplatin (2 arms). Primary endpoint: Relapse-free survival. Started Apr 2013; status: completed.
02
Drugs
etoposidecisplatinirinotecan
03
Conditions
Lung neuroendocrine carcinoma (LNEC)
Beyond the preview
Go deeper on jRCTs031180216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180216.